EMA Provides an Outlook on the Product-Specific Bioequivalence Guidelines Expected in 2026
Recommendation
27-29 October 2026
Practical Approaches for Assessing the Risks of Impurities
On the Road to 30,000 Members
Let us become the World's Leading GMP/GDP Compliance Community in 2026
EMA’s product-specific bioequivalence guidances describe, in a standardised format, how bioequivalence (BE) should be demonstrated.
On 19 May 2026, the EMA added the item “Product-specific guidelines that can be expected for 2026” to its website.
The following products are listed:
- Aripiprazole
- Cladribine
- Etonogestrel
- Fidaxomicin
- Ivacaftor
- Liraglutide
- Naproxen
- Niraparib
- Piribedil
- Raltegravir
- Rifaximin
- Semaglutide (tablets + SC solution)
- Tafamidis
- Tofacitinib
Further information is available on the EMA website.
Related GMP News
19.10.2026EMA Updates Information Page on Bioequivalence Guidelines
19.10.2026BP Publishes new Draft Texts
19.10.2026FDA Identifies Critical Deficiencies in Analytical Testing and CGMP Oversight
07.10.2026Analytical Quality Group Developments May through August 2026
07.10.2026Two New FDA Warning Letters Put OOS Investigations in Focus
07.10.2026Pharmeuropa: Revision Proposed for Chapter 2.5.32 on Coulometric Karl Fischer Water Determination